Patients with metastatic CRPC are commonly treated with second-generation AR antagonists (i.e., enzalutamide), intra-tumor androgen synthesis inhibitors (i.e., abiraterone), radium 223 chloride (approved in PCa patients with bone metastasis), taxane or platinum-based chemotherapy, poly(ADP-ribose)polymerase (PARP) inhibitors (approved in PCa patients with mutations in homologous recombination repair genes), and immune checkpoint inhibitors (approved in PCa patients with metastatic PCa harboring microsatellite instability or mismatch repair defects) [8]. The gene discussed is PARP1; the disease is posterior cortical atrophy.